Compounded Tirzepatide: Is It Safe, Is It Legal, and What Changed?

Compounding is the preparation of a medicine by a pharmacist or physician to meet a specific patient's need that an approved drug cannot meet. The FDA gives examples such as removing an ingredient a patient is allergic to, or making a liquid for someone who cannot swallow a tablet.1

Compounded tirzepatide is usually a vial of injectable solution prepared by a pharmacy, rather than the Zepbound pen or vial made by Eli Lilly. The FDA is explicit about the regulatory difference: compounded drugs are not FDA-approved, which means the agency does not verify their safety, effectiveness or quality before they are marketed.1

Federal law recognizes two kinds of compounder, and the rules for tirzepatide differ between them.

• 503A pharmacies are state-licensed pharmacies. State boards of pharmacy carry primary day-to-day oversight, they do not have to register with the FDA, and they are not held to current good manufacturing practice (CGMP) rules, although the FDA can inspect them.1 They compound for individual patients based on a prescription.2
• 503B outsourcing facilities are a category created in 2013. They register with the FDA, are inspected on a risk-based schedule and must follow CGMP requirements.1

The FDA notes that state-licensed pharmacies that are not outsourcing facilities are not required to report adverse events to the agency.3 You can read more about the registered facilities on our outsourcing facilities page.

Not banned outright, but sharply restricted once the shortage ended. The timeline, as published by the FDA:2

• October 2, 2024: the FDA determined the tirzepatide shortage was resolved. After litigation, that decision was sent back to the agency for reevaluation on October 22, 2024.
• December 19, 2024: the FDA reissued its decision that the shortage was resolved. It gave 503A pharmacies until February 18, 2025 and 503B outsourcing facilities until March 19, 2025 before it would act against copies made under the shortage exemption.
• March 2025: the 503A grace period had ended, and the 503B grace period ran to March 19, 2025.
• April 1, 2026: the FDA restated the conditions compounders must meet and confirmed that tirzepatide is on neither the drug shortage list nor the 503B bulks list.

Since then the FDA has gone further. On April 30, 2026 it proposed to formally exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound them from bulk drug substances.4 Public comments closed on June 29, 2026; the final decision should be checked on the FDA's page before relying on it.4 Our status tracker follows these changes.

It can be, when a 503A pharmacy compounds it for an individual patient and it is not "essentially a copy" of Zepbound or Mounjaro.2

The FDA considers a compounded drug essentially a copy if it has the same active ingredient as the approved product, in the same, similar or easily substitutable strength, and can be used by the same route — unless a prescriber determines and documents that the compounded version produces a significant difference for that identified patient.2 The agency has also said it does not intend to act against a pharmacy that fills four or fewer prescriptions of such a copy in a calendar month.2

For 503B outsourcing facilities, the position is narrower: they may not compound from bulk drug substances unless the substance is on the 503B bulks list or the drug is on the shortage list, and tirzepatide is on neither.2

What this means in plain terms: lawful compounded tirzepatide in 2026 depends on a documented, patient-specific clinical reason. A request for an unusual dose, as in GLP-1 microdosing, is a clinical decision for the prescriber. A product sold to large numbers of people at standard Zepbound-like strengths, with no individual clinical difference, is what the FDA has said compounders may not make regularly or in inordinate amounts.2

The FDA cannot say, because it does not review compounded drugs before they are sold.1 What it has published is a set of specific concerns:

• Adverse event reports. As of May 31, 2026, the FDA had received more than 730 reports of adverse events associated with compounded tirzepatide, and says the true number is likely higher because most pharmacies are not required to report.3
• Dosing errors. Compounded injectables often come in multi-dose vials measured with syringes, and the FDA has received reports, some requiring hospitalization, linked to people measuring the wrong dose.3
• Storage. The FDA advises discarding multi-dose compounded vials 28 days after first use, and not using an injectable GLP-1 that arrives warm.3
• Ingredient sourcing. In September 2025 the FDA set up an import "green list" so that tirzepatide and semaglutide ingredients from facilities it has not verified can be detained at the border.8
• Research peptides. Products labeled "for research purposes" or "not for human consumption" but sold to consumers with dosing instructions are not compounded drugs at all, and the FDA has issued warning letters to sellers of such tirzepatide.3,9

For contrast, Zepbound's label sets out tested doses of 2.5 mg to 15 mg once weekly and a full list of warnings, including a boxed warning about thyroid C-cell tumors seen in rodents.10 The same warnings apply to the molecule however it is made. More on spotting unsafe sellers is on our safety hub.

The FDA has repeatedly warned telehealth companies over how they market compounded GLP-1s. On February 6, 2026 it said it would act against companies claiming compounded products are generic versions of approved drugs, use the same active ingredient as approved drugs, or are clinically proven.6 On March 3, 2026 it announced warning letters to 30 telehealth companies over claims implying sameness with approved drugs and over branding that obscured who actually compounded the product.5

In June 2026 the agency published a list of practices it considers misleading, including calling a compounded drug "FDA-approved," calling it a generic, implying the telehealth company is the compounder, and describing a pharmacy as "FDA-approved" or "FDA-licensed."7 We keep a running list on our warning letters page.

The core difference is approval: Zepbound is FDA-approved and tested in clinical trials; compounded tirzepatide is not.1,10

• Evidence. Zepbound's label rests on its clinical trials.10 Compounded products have not been through FDA review for safety, effectiveness or quality.1
• Form and dosing. Zepbound comes in single-dose vials and pens at set strengths.10 Compounded products vary by pharmacy, and multi-dose vials raise the dosing-error risk described above.3
• Price. LillyDirect now sells Zepbound vials and KwikPens from $299 a month at 2.5 mg, $399 at 5 mg and $449 at higher doses when refilled within 45 days.11 That narrows the gap many people turned to compounding for.

The same rules apply to semaglutide, covered in our compounded semaglutide guide. For a fuller comparison, see compounded tirzepatide vs Zepbound and our cheapest compounded tirzepatide ranking.

Lawful access starts with a licensed prescriber and a state-licensed pharmacy. The FDA's advice is to obtain a prescription and fill it at a state-licensed pharmacy, and it points consumers to its BeSafeRx resources for buying medicines online.3

Before using any compounded tirzepatide online, it is reasonable to check:

• Who compounds it. The FDA expects telehealth companies to name the actual pharmacy rather than present the product as their own.7
• Whether it is presented as approved or generic. The FDA treats both claims as misleading for compounded drugs.7
• Whether there is a clinical reason documented. That is the basis on which a copy of an approved drug can lawfully be compounded.2
• The full cost and any membership terms. The FTC has acted against a GLP-1 telehealth seller over undisclosed costs and membership commitments.12 Asking whether compounded tirzepatide is available without a membership, and what cancelling involves, is part of the same check.

Is compounded tirzepatide the same as Zepbound? No. It may contain the same active ingredient, but it is not FDA-approved, and the FDA treats claims that compounded drugs are "the same as" or "generic versions of" approved drugs as misleading.1,7

Is compounded tirzepatide still available? Some 503A pharmacies may still compound it for individual patients with a documented clinical need. Outsourcing facilities may not compound it from bulk ingredients while it is off the shortage list and off the 503B bulks list.2

When did the tirzepatide shortage end? The FDA reissued its decision that the shortage was resolved on December 19, 2024.2

Are compounded GLP-1s safe? The FDA does not verify their safety before sale and has received more than 730 adverse event reports for compounded tirzepatide as of May 31, 2026.1,3

Is research-grade tirzepatide legal to buy? Products labeled "for research purposes" or "not for human consumption" and sold for people to inject are not lawful compounded drugs, and the FDA has warned sellers of them.3,9

If you want to compare the providers that still offer compounded tirzepatide with documented pharmacy sourcing, see our ranking of the best compounded tirzepatide providers, or the tirzepatide online guide for brand-name options.

This article is for information only and is not medical or legal advice. Compounded drugs are not FDA-approved. Talk to a licensed clinician before starting or switching any GLP-1 treatment.